Platelets play a major role in preventing bleeding. The possibility of producing platelets in vitro is of major interest in a context where the number of therapies affecting the platelet count is increasing. In vivo, platelets are produced by megakaryocytes (MKs) that derive from hematopoietic stem cells (HSCs) located in the bone marrow. In vivo, MK can release about 2,000 platelets, whereas platelet production in vitro from CSH remains ineffective (10 platelets / megakaryocyte). The project developed by our team aims to improve the conditions of platelet production in vitro. We have recently shown that an aryl hydrocarbon receptor antagonist, allows in our culture conditions to improve by 5 times the platelet production and promotes the emergence of a hematopoietic population which could be more competent for platelet production. The proposed project will focus on characterizing this emerging population according to three criteria: i) the phenotype (flow cytometry) ii) the megakaryoblastic potential (clonogenic test, RNA profile) and iii) the ability to produce platelets (cell culture)

Characterization of a competent progenitor for in vitro platelet production

Technologies acquired at the end of the M2 internship:

  • Cell culture from hematopoietic stem cells,
  • Flow cytometry and cell sorting,
  • Molecular biology

Manager : Christian Gachet

Team «Biology of thrombopoiesis» – François Lanza

Internship manager : Catherine STRASSEL


Candidate recruited in the specialty:

Master pathophysiology : From Molecule to Man – Master BMC